SA521422394B1 - Ccr8 جسم مضاد جديد لـ - Google Patents

Ccr8 جسم مضاد جديد لـ

Info

Publication number
SA521422394B1
SA521422394B1 SA521422394A SA521422394A SA521422394B1 SA 521422394 B1 SA521422394 B1 SA 521422394B1 SA 521422394 A SA521422394 A SA 521422394A SA 521422394 A SA521422394 A SA 521422394A SA 521422394 B1 SA521422394 B1 SA 521422394B1
Authority
SA
Saudi Arabia
Prior art keywords
novel anti
ccr8 antibody
antibody
ccr8
novel
Prior art date
Application number
SA521422394A
Other languages
English (en)
Inventor
ناكامورا إتسو
تاناكا اتسوشي
كاواشيما اتسوناري
تاكاهاشي تاتسويا
مياوتشي تسوجو
يوشيدا تيتسويا
اونودا جونجي
إماي سوناو
ساكاجوتشي شيمون
فوروكاوا كينتارو
يوشيكاوا ماي
ناجيرا موريو
اوهكورا ناجاناري
وادا هيساشي
Original Assignee
شيونوجي آند كو.، ليمتد.
أوساكا يونيفيرستي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by شيونوجي آند كو.، ليمتد., أوساكا يونيفيرستي filed Critical شيونوجي آند كو.، ليمتد.
Publication of SA521422394B1 publication Critical patent/SA521422394B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي بجسم مضاد جديد لـ CCR8 novel anti-CCR8 antibody. يمكن استخدام الجسم المضاد antibody لعلاج treating أو الوقاية من السرطانات preventing cancers أو ما شابه ذلك. شكل 1.
SA521422394A 2018-12-27 2021-06-24 Ccr8 جسم مضاد جديد لـ SA521422394B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018245044 2018-12-27
JP2019099923 2019-05-29

Publications (1)

Publication Number Publication Date
SA521422394B1 true SA521422394B1 (ar) 2024-05-09

Family

ID=71128288

Family Applications (1)

Application Number Title Priority Date Filing Date
SA521422394A SA521422394B1 (ar) 2018-12-27 2021-06-24 Ccr8 جسم مضاد جديد لـ

Country Status (13)

Country Link
US (1) US20220064312A1 (ar)
EP (1) EP3903817A4 (ar)
JP (3) JP6894086B2 (ar)
KR (1) KR20210108996A (ar)
CN (1) CN113260381A (ar)
AU (1) AU2019415395A1 (ar)
BR (1) BR112021011431A2 (ar)
CA (1) CA3124332A1 (ar)
MX (1) MX2021007576A (ar)
SA (1) SA521422394B1 (ar)
SG (1) SG11202106214YA (ar)
TW (1) TW202039575A (ar)
WO (1) WO2020138489A1 (ar)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102144658B1 (ko) 2017-03-29 2020-08-14 시오노기세이야쿠가부시키가이샤 암 치료용 의약 조성물
TW202039575A (zh) * 2018-12-27 2020-11-01 日商鹽野義製藥股份有限公司 新穎之抗ｃｃｒ８抗體
CN115087488A (zh) 2020-02-14 2022-09-20 震动疗法股份有限公司 与ccr8结合的抗体和融合蛋白及其用途
MX2022011701A (es) 2020-03-23 2022-10-07 Bristol Myers Squibb Co Anticuerpos anti-receptor de quimiocina 8 con motivo c-c (ccr8) para el tratamiento del cancer.
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
EP4173636A4 (en) 2020-06-30 2024-08-28 Shionogi & Co COMBINED USE OF ANTI-CCR8 ANTIBODY AND CHEMOTHERAPEUTIC
CN117098561A (zh) * 2020-08-28 2023-11-21 和铂医药美国股份有限公司 Ccr8抗体及其应用
AU2021360782A1 (en) * 2020-10-14 2023-06-08 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
EP4010378A4 (en) * 2020-10-16 2023-07-26 LaNova Medicines Limited ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
CA3206125A1 (en) 2020-12-24 2022-06-30 Vib Vzw Murine cross-reactive human ccr8 binders
US20240076391A1 (en) 2020-12-24 2024-03-07 Oncurious Nv Human ccr8 binders
CA3206124A1 (en) 2020-12-24 2022-06-30 Vib Vzw Non-blocking human ccr8 binders
CN114805569A (zh) * 2021-01-29 2022-07-29 北京伟峰益民科技有限公司 一种抗人ccl1抗体及其应用
CN117295820A (zh) 2021-03-31 2023-12-26 盐野义制药株式会社 以ccr8作为抗原识别的嵌合抗原受体
PE20240363A1 (es) * 2021-06-04 2024-03-04 Amgen Inc Anticuerpos anti-ccr8 y usos de los mismos
MX2023014415A (es) * 2021-06-04 2024-02-08 Amgen Inc Moléculas de acoplamiento de linfocitos t y usos de las mismas.
EP4370553A1 (en) 2021-07-14 2024-05-22 Genentech, Inc. Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
TW202321304A (zh) * 2021-07-27 2023-06-01 美商艾伯維有限公司 抗ｃｃｒ８抗體
EP4388009A1 (en) * 2021-08-20 2024-06-26 HiFiBiO, Inc. Anti-ccr8 antibodies and uses thereof
KR20240091056A (ko) 2021-10-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 피리디진-3(2h)-온 유도체
CN118201941A (zh) 2021-10-29 2024-06-14 吉利德科学公司 Cd73化合物
AU2022400921A1 (en) * 2021-12-02 2024-06-27 Zai Lab (Shanghai) Co., Ltd. Ccr8 antigen binding unit and uses thereof
CA3239528A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023116880A1 (en) * 2021-12-23 2023-06-29 Concept To Medicine Biotech Co., Ltd. Anti-ccr8 antibodies and uses thereof
WO2023137466A2 (en) * 2022-01-14 2023-07-20 Qilu Puget Sound Biotherapeutics Corporation Anti-ccr8 antibodies
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN116789820A (zh) * 2022-03-18 2023-09-22 北京天诺健成医药科技有限公司 一种新型免疫调节剂的开发和应用
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023206350A1 (en) * 2022-04-29 2023-11-02 Analytical Biosciences Shanghai Limited Anti-ccr8 antibodies and uses thereof
WO2023219147A1 (ja) * 2022-05-13 2023-11-16 塩野義製薬株式会社 Ｃｃｒ８検出用新規抗ｃｃｒ８抗体
WO2023230473A1 (en) 2022-05-24 2023-11-30 Bristol-Myers Squibb Company Antibodies that bind to human ccr8
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024008110A1 (zh) * 2022-07-07 2024-01-11 四川思柏沃生物技术有限公司 抗ccr8抗体及其应用
TW202413426A (zh) * 2022-08-04 2024-04-01 英屬開曼群島商百濟神州有限公司 抗ｃｃｒ８抗體及使用方法
WO2024052517A2 (en) 2022-09-09 2024-03-14 Bayer Aktiengesellschaft Medical use of ccr8 antibodies and dosing schedule
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
TW202421664A (zh) 2022-10-07 2024-06-01 美商建南德克公司 用抗ｃ—ｃ模體趨化因子受體８（ｃｃｒ８）抗體治療癌症之方法
CN118146368A (zh) * 2022-12-07 2024-06-07 广东菲鹏制药股份有限公司 抗ccr8抗体及其应用
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024165470A1 (en) 2023-02-06 2024-08-15 Bayer Aktiengesellschaft Combinations of dgk (diacylglycerol kinase) inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7949394A (en) 1993-11-19 1995-06-06 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
RU2198220C2 (ru) 1996-09-26 2003-02-10 Чугаи Сейяку Кабусики Кайся Антитело против белка, родственного паращитовидному гормону человека, днк, вектор, способ получения и использование антитела
WO1999006561A2 (en) * 1997-07-29 1999-02-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Chemokine receptor ccr8 dna and uses thereof
WO1999025734A2 (en) * 1997-11-13 1999-05-27 Schering Corporation Th2 CELL DEPLETION; COMPOSITIONS; METHODS
US6762341B2 (en) * 2000-02-10 2004-07-13 Schering Corporation Uses of mammalian CCR8 receptors and related reagents
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
WO2013131010A2 (en) * 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
AU2017266686B2 (en) 2016-05-16 2023-03-09 Checkmab S.R.L Markers selectively deregulated in tumor-infiltrating regulatory T cells
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
KR102144658B1 (ko) * 2017-03-29 2020-08-14 시오노기세이야쿠가부시키가이샤 암 치료용 의약 조성물
WO2019157098A1 (en) * 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
TW202039575A (zh) 2018-12-27 2020-11-01 日商鹽野義製藥股份有限公司 新穎之抗ｃｃｒ８抗體

Also Published As

Publication number Publication date
AU2019415395A1 (en) 2021-07-15
JP2021101710A (ja) 2021-07-15
JP2024059872A (ja) 2024-05-01
EP3903817A4 (en) 2022-08-17
BR112021011431A2 (pt) 2021-11-23
JP6894086B2 (ja) 2021-06-23
TW202039575A (zh) 2020-11-01
SG11202106214YA (en) 2021-07-29
EP3903817A1 (en) 2021-11-03
WO2020138489A1 (ja) 2020-07-02
CA3124332A1 (en) 2020-07-02
CN113260381A (zh) 2021-08-13
JP7452818B2 (ja) 2024-03-19
US20220064312A1 (en) 2022-03-03
MX2021007576A (es) 2021-08-24
JPWO2020138489A1 (ja) 2021-02-18
KR20210108996A (ko) 2021-09-03

Similar Documents

Publication Publication Date Title
SA521422394B1 (ar) Ccr8 جسم مضاد جديد لـ
PH12020500398A1 (en) Antibody-pyrrolobenzodiazepine derivative conjugate
IL276830A (en) Anti-claudin 18.2 antibodies and uses thereof
SG10202111141WA (en) Anti-claudin 18.2 antibodies and uses thereof
IL277072A (en) Anti-claudin antibodies 18.2
EP3878863A4 (en) ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
PH12021550152A1 (en) Anti-cd112r compositions and methods
ZA202103061B (en) Anti-cldn18.2 antibody and uses thereof
MY198605A (en) Maytansinoid derivatives conjugates thereof, and methods of use
ZA202106880B (en) Anti-claudin 18.2 antibody and application thereof
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
PH12021550558A1 (en) Modulators of pnpla3 expression
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
TN2019000211A1 (en) Antitumoral compounds
MX2020009147A (es) Moduladores de la expresion de irf4.
MX2020007369A (es) Moduladores de la expresion de dnm2.
JOP20210107A1 (ar) مضمنات التعبير عن foxp3
MX2020010721A (es) Moduladores de la expresion de ezh2.
AU201815763S (en) Quick connection coupler
MX2022005959A (es) Anticuerpo anti-pcsk9 y uso del mismo.
CA187846S (en) Inverter
SG11202008612XA (en) Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis
MX2019002142A (es) Super complemento alimenticio mejorado para perros y su proceso de fabricacion.